A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.
ONCOLOGY® Companion, Volume 38, Supplement 10
Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.
A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.
Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
4
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
5
